Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Aug 24, 2005
OXiGENE Adds Accomplished Pharmaceutical Executive, Dr. Richard Chin, to Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 24, 2005-- -- Pharma Veteran and Board Certified Internist Brings Successful Product Launch Track Record at Elan Corporation, Genentech and Procter & Gamble Pharmaceuticals to Waltham-Based Biotech Company --...

Aug 23, 2005
OXiGENE Announces Positive Preclinical Data on OXi4503; Independent Research Further Illustrates the Mechanism and Therapeutic Potential of Novel Ortho-Quinone Drug Candidate in Cancer

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 23, 2005-- -- Studies Indicate Effectiveness of Candidate as a Single Agent and Use in Combination Therapies -- At the Tumor Microenviron...

Aug 23, 2005
Positive Clinical Trial Data in Oncology Presented for CA4P, OXiGENE's Vascular Disruption Agent

WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 23, 2005--OXiGENE, Inc. Combretastatin A4 Prodrug in Combination Trials with Chemotherapy Indicates Anti-Tumor Activity and is Well Tolerated, No Drug-Related Serious Adverse Events or Dose-Limiting Toxicity Observ...

Jul 28, 2005
OXiGENE to Present at America's Growth Capital 2nd Annual Growth Conference: August 1st Presentation Available via Live Webcast

WALTHAM, Mass.--(BUSINESS WIRE)--July 28, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that its Head of Research and Development and Chief Scientific Officer, Dr. David Cha...

Jul 27, 2005
OXiGENE Reports Second-Quarter 2005 Operational and Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--July 27, 2005--Recent developments: Announced Positive Phase Ib Update of CA4P with Radiotherapy at ASCO - CA4P well tolerated with radiotherapy for lung and prostate cancers, anti-tumor activity...

Jul 20, 2005
OXiGENE to Webcast Second-Quarter 2005 Financial Results Conference Call; Live Internet Webcast to be Available at www.oxigene.com

WALTHAM, Mass.--(BUSINESS WIRE)--July 20, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's second-quarter 2005 financial results conference call at 10:00 a.m. ET Wednesday, July 27, 2005. President and Chief Executive Officer Fred Driscoll, Chief Financial Officer James Murphy...

Jun 20, 2005
OXiGENE Provides Update on Vascular Targeting Programs in Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--June 20, 2005--OXiGENE, Inc. (NASDAQ and XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today provided a mid-year update on the progress of its programs for vascular targeting agents (VTAs) in ...

May 27, 2005
OXiGENE to Present at Friedman Billings Ramsey Ninth Annual Growth Conference: June 1st at 11am

WALTHAM, Mass.--(BUSINESS WIRE)--May 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present an overview of t...

May 16, 2005
OXiGENE Announces Positive Phase Ib Update of CA4P with Radiotherapy at ASCO

-CA4P well tolerated with radiotherapy for lung and prostate cancers, anti-tumor activity observed- WALTHAM, Mass.--(BUSINESS WIRE)--May 16, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that a clinical investigator studying the C...

May 13, 2005
OXiGENE Announces Presentation at ASCO of Positive Tumor Response Data in Phase Ib Trial of CA4P With Chemotherapy

Clinical Investigator Reports that CA4P in Combination with Carboplatin and/or Paclitaxel Indicates Anti-tumor Activity and No Unexpected Toxicity WALTHAM, Mass.--(BUSINESS WIRE)--May 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN...

FirstPrevious
...
34
NextLast
= add release to Briefcase